Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Stock Is Shorted More

October 2, 2018 - By olga

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Logo

Investors sentiment increased to 1.61 in Q2 2018. Its up 0.21, from 1.4 in 2018Q1. It improved, as 33 investors sold Alnylam Pharmaceuticals, Inc. shares while 60 reduced holdings. 57 funds opened positions while 93 raised stakes. 92.05 million shares or 3.13% more from 89.26 million shares in 2018Q1 were reported.
Northern Trust Corporation holds 499,048 shares. Ckw has invested 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Frontier Mgmt Limited Liability Corp has 0.03% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 36,200 shares. Century Cos invested 0.04% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Opus Point Ptnrs Management Ltd Liability Co holds 14,112 shares or 3.01% of its portfolio. 17,110 are owned by Employees Retirement Association Of Colorado. Regions invested in 0% or 10 shares. Piedmont Investment Advsrs Ltd Llc holds 4 shares. 287,714 are held by Tobam. Amp Capital holds 0.02% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 36,428 shares. Sg Americas Secs Limited Co owns 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 4,778 shares. Gru One Trading Limited Partnership has invested 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). 4,736 are held by M&T State Bank Corp. 3,309 were reported by Neuberger Berman Group Limited Liability Corporation. Emory University invested in 26,256 shares or 1.72% of the stock.

Since April 16, 2018, it had 0 insider buys, and 4 sales for $7.24 million activity. CLARKE JOHN K also sold $1.50M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Thursday, May 31. 50,000 shares were sold by MARAGANORE JOHN, worth $5.27 million. Another trade for 1,563 shares valued at $164,178 was sold by KEATING LAURIE.

The stock of Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) registered an increase of 10.06% in short interest. ALNY’s total short interest was 5.98 million shares in October as published by FINRA. Its up 10.06% from 5.43M shares, reported previously. With 1.03M shares average volume, it will take short sellers 6 days to cover their ALNY’s short positions. The short interest to Alnylam Pharmaceuticals Inc’s float is 6.7%.

The stock increased 0.93% or $0.81 during the last trading session, reaching $88.33. About 597,358 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 19.20% since October 2, 2017 and is uptrending. It has outperformed by 3.58% the S&P500.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company has market cap of $8.89 billion. The Company’s pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. It currently has negative earnings. The companyÂ’s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis ; Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 9 analysts covering Alnylam Pharma (NASDAQ:ALNY), 7 have Buy rating, 1 Sell and 1 Hold. Therefore 78% are positive. Alnylam Pharma had 18 analyst reports since April 3, 2018 according to SRatingsIntel. The stock has “Reduce” rating by Nomura on Monday, August 13. Stifel Nicolaus maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Monday, August 13. Stifel Nicolaus has “Buy” rating and $123 target. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Stifel Nicolaus on Tuesday, August 7. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given on Wednesday, June 27 by Piper Jaffray. The firm has “Buy” rating given on Monday, April 23 by Piper Jaffray. On Thursday, September 13 the stock rating was maintained by Stifel Nicolaus with “Buy”. The rating was maintained by BMO Capital Markets with “Outperform” on Monday, August 13. Morgan Stanley maintained the stock with “Equal-Weight” rating in Monday, May 7 report. Morgan Stanley maintained it with “Equal-Weight” rating and $87 target in Friday, September 28 report. The rating was maintained by Morgan Stanley on Monday, August 13 with “Equal-Weight”.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Globenewswire.com which released: “KESSLER TOPAZ MELTZER & CHECK, LLP – Announces Investor Securities Fraud Class Action Lawsuit Against …” on October 01, 2018, also Seekingalpha.com with their article: “Alnylam submits Onpattro marketing application in Japan” published on September 28, 2018, Seekingalpha.com published: “Making Sense Of Alnylam’s Valuation” on September 24, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on October 01, 2018 as well as Globenewswire.com‘s news article titled: “Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Alnylam Pharmaceuticals, Inc …” with publication date: September 29, 2018.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>